Key result
Molecular modeling of 107 6-aminonicotinate-based compounds identified key hydrophobic and hydrogen bond interactions and specific amino acid residues crucial for P2Y12 antagonist activity.
Molecular modeling identified key structural features and binding residues of 6-aminonicotinate-based compounds to the P2Y12 receptor, providing insights for the design of novel anti-platelet agents.
Does not support clinical use; leaves open whether identified interactions yield viable P2Y12 antagonists.
P2Y12 receptor is an attractive target for the anti-platelet therapies, treating various thrombotic diseases. In this work, a total of 107 6-aminonicotinate-based compounds as potent P2Y12 antagonists were studies by a molecular modeling study combining three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking and molecular dynamics (MD) simulations to explore the decisive binding conformations of these antagonists with P2Y12 and the structural features for the activity. The optimum CoMFA and CoMSIA models identified satisfactory robustness and good predictive ability, with R2 = .983, q2 = .805, = .881 for CoMFA model, and R2 = .935, q2 = .762, = .690 for CoMSIA model, respectively. The probable binding modes of compounds and key amino acid residues were revealed by molecular docking. MD simulations and MM/GBSA free energy calculations were further performed to validate the rationality of docking results and to compare the binding modes of several compound pairs with different activities, and the key residues (Val102, Tyr105, Tyr109, His187, Val190, Asn191, Phe252, His253, Arg256, Tyr259, Thr260, Val279, and Lys280) for the higher activity were pointed out. The binding energy decomposition indicated that the hydrophobic and hydrogen bond interactions play important roles for the binding of compounds to P2Y12. We hope these results could be helpful in design of potent and selective P2Y12 antagonists.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2016) studied Thrombotic diseases. 6-aminonicotinate-based compounds was evaluated on Binding mechanism and structural features for activity with P2Y12. Molecular modeling of 107 6-aminonicotinate-based compounds identified key hydrophobic and hydrogen bond interactions and specific amino acid residues crucial for P2Y12 antagonist activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: